The Effects of DPPIs on Cognitive Function of Diabetic Patients

Beni-Suef University105 enrolled

Overview

This is a single-center, randomized controlled clinical trial with a parallel-group design conducted at Minia University hospital.

All patients admitted to Diabetes clinics of Minia University Hospital, will be screened for the eligibility criteria. diabetic patients (aged above 50 years) with uncontrolled diabetes on oral hypoglycemic drugs. 105 patients will be enrolled and randomized into three groups. Group I=35 T2DM patients given DPP4Is Group II=35 T2DM patients given DPP4Is and metformin. Group III=35 patients will be given placebo (only adjust their drugs to control blood glucose level)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

105

Conditions

Cognitive Impairment

Interventions

Control groupDRUG

35 T2DM patients will be given placebo (only adjust their drugs to control blood glucose level)

DPP-4 inhibitor groupDRUG

35 T2DM patients will be given DPP-4 I once or twice daily

DPP-4 inhibitor + metformin groupDRUG

35 T2DM patients will be given DPP-4 I + metformin once or twice daily

Eligibility

Sex: ALLMin age: 45 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: Type-2 diabetic adult subjects (above 50 years old) who had uncontrolled (A1c=8-9 %) blood glucose levels with an oral hypoglycemic drug at the screening visit were eligible to participate. Exclusion Criteria: Those with type1 diabetes or ketoacidosis, end organ failure as chronic renal failure (estimated serum creatinine level ≥ 1.5mg/dl in male and ≥ 1.4mg/dl in female), liver cell failure (elevated alanine transaminase (ALT) and aspartate transaminase (AST) ≥ 2 folds), and heart failure, previous history of pancreatitis, and pregnant or lactating females were excluded from the study.

Locations (1)

Minia University hospital

Minya, Egypt